With Key US Patent Upheld, Benitec Sets Sights on 'Relaunch,' $8.4M Financing

Benitec said the funding will largely be used to advance its three preclinical drug-development programs, at least one of which is expected to enter human testing within two years.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.